Subjective and objective evaluation of acoustic therapies for tinnitus patients

ISRCTN ISRCTN14553550
DOI https://doi.org/10.1186/ISRCTN14553550
Secondary identifying numbers CONBIOETICA19CEI00820130520
Submission date
24/10/2017
Registration date
31/10/2017
Last edited
18/07/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Ear, Nose and Throat
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Background and study aims
A large number of acoustic therapies (sound therapy) are used to treat tinnitus (a condition where a person hears sounds that come from inside the body). At present, the only way to evaluate acoustic therapies is by means of subjective methods such as analog visual scale and questionnaires. This study, consequently, seeks to establish an objective methodology to treat tinnitus with acoustic therapies based on electroencephalographic (EEG) activity recordings (the recordings of the electrical activity in the brain). The aim of this study is to examine how acoustic therapies can improve the quality of life and is there is way to correlate the objective and subjective data from patients EEGs and questionnaires.

Who can participate?
Patients aged 18 with tinnitus.

What does the study involve?
Participants are randomly allocated to one of five groups. There are four acoustic therapy groups and one control group. Participants in the acoustic therapy groups, each group using different acoustics and effects, undergo EEG recordings at the beginning of the treatment, one week of treatment, five weeks of treatment and at eight weeks of treatment. Those in the control group listen to relaxing music and do not receive any acoustic therapy. Participants are assessed for their effectiveness of the treatments.

What are the possible benefits and risks of participating?
Participants may benefit from decreases in their tinnitus symptoms. There are no expected risks however it could increase the tinnitus symptoms.

Where is the study run from?
Tecnológico de Monterrey (Mexico)

When is the study starting and how long is it expected to run for?
June 2016 to December 2017

Who is funding the study?
Tecnológico de Monterrey (Mexico)

Who is the main contact?
Dr Luz María Alonso Valerdi

Study website

Contact information

Dr Luz María Alonso Valerdi
Scientific

TEC MONTERREY
Monterrey Institute of Technology and Higher Education
Eugenio Garza Sada 2501
Monterrey
64849
Mexico

Study information

Study designInterventional randomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Study type Participant information sheet
Scientific titleElectroencephalographic evaluation of acoustic therapies for the treatment of chronic and refractory tinnitus
Study hypothesisResearch questions:
1. How can acoustic therapies improve the quality of patients ́life?
2. How can we correlate objective and subjective data from patients EEG and questionnaires?
Ethics approval(s)1. Research Ethics Committee of Escuela de Medicina del Instituto Tecnológico y de Estudios Superiores de Monterrey, 20/06/2016, ref: COFEPRIS register number 13CEI19039139
2. Research Committee of Escuela de Medicina del Instituto Tecnológico y de Estudios Superiores de Monterrey with the National Commission of Bioethics register number, 20/06/2016, refs: COFEPRIS register number 13CI19039138 and CONBIOETICA19CEI00820130520
ConditionChronic and refractory tinnitus
InterventionParticipants are randomly allocated to one of five different acoustic therapies (control and 4 other standard ones).

The acoustic therapies used in the study are the ones found up to now as the most effective. These are tinnitus retraining therapy, auditory discrimination therapy, tinnitus retraining therapy, therapy for enriched acoustic environment, and binaural. All of them are acoustically different and reach different effects. For example, binaural therapy attempts to reduce the stress level and thereby to reduce the tinnitus perception. Auditory discrimination therapy attempts to redirect the patient attention towards therapy instead to tinnitus, and thus diminishing the mental resources used to perceive tinnitus.

The control therapy includes relaxing music instead of any acoustic therapy. It is used as reference to compare the other acoustic therapies.

All participants are made aware of the procedure and signed a consent form. Acoustic therapies are personalized for each patient and their head physician followed-up the experiment. Participants are instructed to use their therapies every day for one hour, at any time of the day. Assistance during the experiment are provided.

In 1st step, evoked activity are considered (EEG data recorded in passive mode) since auditory ERPs have been formerly investigated in patients with tinnitus, as well as in those with tinnitus treated with acoustic therapies. For each experimental session in passive mode, patients will be asked to close their eyes, relax and pay attention to their stimulus. All the stimuli are 1 second long, repeated 50 times, and have an inter-stimulus interval of 2.5 seconds.

In the 2nd step of the same session, active mode is recorded. A usual acoustic environment are played, whilst five associated auditory stimuli are randomly played. Participants are instructed to identify the randomized stimuli by pressing a keyboard button. The three acoustic environments along with their related stimuli in each session are standardised to 1 second and repeated 50 times at a random rate.

In total, four sessions are recorded: at the beginning of the experiment, at one week of treatment, at five weeks of treatment, and at eight weeks of treatment.

To record the data, 17 EEG channels are recorded at 256Hz by using the g.USBamp (g.tec medical enginnering, Austria).
Intervention typeOther
Primary outcome measureEffectiveness of each therapy is assessed using the EEG registration at the beginning of the procedure, one week after beginning, five weeks after beginning, and eight weeks
Secondary outcome measuresState and therapy effectiveness is measured using validated patient questionnaires at week one, week five and week eight
Overall study start date20/06/2016
Overall study end date31/07/2019

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants75 patients, to have 5 groups (15 patients per group)
Total final enrolment102
Participant inclusion criteria1. Patients adults (>18 years old)
2. Accept voluntarily to participate in the project
3. Sign a consent form
Participant exclusion criteria1. Without any history of otitis
2. Cerebellopontine angle tumours
3. Psychiatrist pathologies
4. Demyelinating diseases of the nervous system
5. Epilepsy
Recruitment start date01/07/2017
Recruitment end date20/11/2017

Locations

Countries of recruitment

  • Mexico

Study participating centres

Tecnologico de Monterrey
Av. Eugenio Garza Sada 2501 Col. Tecnologico Sur
Monterrey
64849
Mexico
Instituto Nacional de Rehabilitación (INR)
Calzada México Xochimilco No. 289
Colonia Arenal de Guadalupe
Alcaldía Tlalpan
Mexico City
14389
Mexico

Sponsor information

Tecnológico de Monterrey
University/education

Monterrey Institute of Technology and Higher Education
Eugenio Garza Sada 2501
Monterrey
64849
Mexico

Website http://tec.mx
ROR logo "ROR" https://ror.org/03ayjn504

Funders

Funder type

Government

Instituto Tecnológico y de Estudios Superiores de Monterrey
Private sector organisation / Other non-profit organizations
Alternative name(s)
Tecnológico de Monterrey, Tec de Monterrey, Monterrey Institute of Technology, Monterrey Institute of Technology and Higher Education, ITESM, Tec
Location
Mexico

Results and Publications

Intention to publish date31/08/2019
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryData sharing statement to be made available at a later date
Publication and dissemination planThis protocol was submitted to the "BMC Ear, Nose and Throat Disorders" and is pending to be published.
IPD sharing planThe current data sharing plans for the current study are unknown and will be made available at a later date. Once we have completed our registrations (possibly by the end of this year) and we have published our first results (possibly by June 2018), we’ll share our databases.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol 28/11/2017 Yes No
Basic results 30/09/2019 30/09/2019 No No
Participant information sheet 18/07/2022 No Yes
Results article 01/07/2022 18/07/2022 Yes No
Results article 26/01/2022 18/07/2022 Yes No
Results article 01/01/2022 18/07/2022 Yes No
Results article 01/11/2021 18/07/2022 Yes No

Additional files

ISRCTN14553550_BasicResults_30Sept2019.pdf
uploaded 30/09/2019

Editorial Notes

18/07/2022: The following changes were made to the trial record:
1. The trial website was added.
2. A link to the participant information sheet was added.
3. The trial participating centre address was updated.
30/09/2019: The following changes were made to the trial record:
1. The basic results of this trial have been uploaded as an additional file.
2. The total final enrolment was added.
19/12/2018: The intention to publish date has been changed from 01/03/2018 to 31/08/2019.
12/12/2018: The overall trial end date has been updated from 22/12/2017 to 31/07/2019.
15/02/2018: Publication reference added.